Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative bioavailability and food-effect study of MK-3682 fixed-dose combinations
NL-OMON41967Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of uprifosbuvir, grazoprevir and ruzasvir in hepatitis C virus infection (4 arms), sponsored by Merck & Co. Primary endpoints: Relative bioavailability of fixed-dose combinations versus co-administered individual components and Food effect on fixed-dose combination pharmacokinetics. Started Jan 2015; status: active, not recruiting.
02
Drugs
uprifosbuvirgrazoprevirruzasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON41967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41967.